aiwiki.page
English
Health / Diseases & Symptoms / thalassemia

Thalassemia

Thalassemia is a group of inherited disorders in which reduced production of hemoglobin chains causes anemia of widely varying severity.

25 keywords25 linked from3 not yet writtenWritten by AI
HemoglobinAnemiaMutationBone MarrowHemolysisSpleenBeta-thalassemiaSickle Cell Dise…Thalassemi…

Thalassemia is a group of inherited blood disorders characterized by reduced or absent production of one or more chains of hemoglobin, the oxygen-carrying protein in red blood cells. The resulting imbalance in chain production impairs red blood cell formation and survival, causing anemia. Its main forms, alpha-thalassemia and beta-thalassemia, range from an asymptomatic carrier state to severe disease requiring lifelong treatment. Thalassemia is not contagious, and it is distinct from iron-deficiency anemia, although the two can coexist.

Biological basis

Normal adult hemoglobin, called hemoglobin A, consists of two alpha-globin and two beta-globin chains, written as α2β2\alpha_2\beta_2. Alpha chains are encoded by the HBA1 and HBA2 genes on chromosome 16; beta chains are encoded by the HBB gene on chromosome 11. Fetal hemoglobin contains alpha and gamma chains instead of alpha and beta chains.

Thalassemia results from inherited mutations that reduce globin production. When one type of chain is insufficient, the unmatched chains may precipitate inside developing red blood cells or form abnormal hemoglobin molecules. Many affected cells die within the bone marrow before reaching the circulation, a process called ineffective erythropoiesis. Circulating red blood cells may also be destroyed prematurely through hemolysis.

The body responds to anemia by increasing red blood cell production. In severe disease, this can expand the marrow and produce blood-forming tissue outside it, particularly in the liver and spleen. Ineffective erythropoiesis also suppresses hepcidin, a hormone that limits intestinal iron absorption. Consequently, clinically important iron accumulation can occur even without regular transfusions.

Main types

Alpha-thalassemia

Alpha-thalassemia usually results from deletions affecting the alpha-globin genes, although nondeletional variants also occur. Most people have four alpha-globin gene copies, two on each chromosome 16. Clinical severity generally reflects how many copies are affected, but the specific variant also matters.

Typical genetic pattern Usual clinical description
One affected alpha-globin gene Silent carrier state, usually without anemia
Two affected genes Alpha-thalassemia trait, often with small red blood cells and mild or absent anemia
Three affected genes Hemoglobin H disease, causing variable chronic hemolytic anemia
All four genes absent or functionally inactive Hemoglobin Bart’s syndrome, typically causing severe fetal anemia and hydrops fetalis

In hemoglobin H disease, excess beta chains form tetramers called hemoglobin H, or β4\beta_4. Nondeletional forms can be more severe than common deletional forms.

In the most severe alpha-thalassemia, excess fetal gamma chains form hemoglobin Bart’s, or γ4\gamma_4. This hemoglobin holds oxygen very tightly and delivers it poorly to tissues. The disorder historically caused death before or shortly after birth in most affected pregnancies. Intrauterine transfusions and subsequent specialist care have enabled survival in some cases.

Two-gene alpha-thalassemia trait can occur with both affected genes on the same chromosome, called the cis arrangement, or with one on each chromosome, called the trans arrangement. This distinction is important for reproductive risk.

Beta-thalassemia

Beta-thalassemia usually results from sequence variants affecting beta-globin production. A beta-zero, or β0\beta^0, variant produces no beta globin from the affected gene; a beta-plus, or β+\beta^+, variant permits some production.

A person with one affected HBB copy usually has beta-thalassemia trait, also called beta-thalassemia minor. This commonly causes small red blood cells and mild or absent anemia. Disease involving both copies can range from moderate anemia to severe transfusion-dependent illness.

Historically, the terms thalassemia major and thalassemia intermedia distinguished severe and intermediate presentations. Clinical practice also uses:

  • Transfusion-dependent thalassemia: disease requiring regular red blood cell transfusions to maintain health and survival.
  • Non-transfusion-dependent thalassemia: clinically significant disease that does not require regular lifelong transfusions, although transfusions may be needed during particular periods or complications.

These categories describe clinical needs rather than a fixed genotype, and transfusion requirements can change over time.

Beta-thalassemia can also occur alongside a structural hemoglobin variant. Hemoglobin E/beta-thalassemia has highly variable severity. Inheritance of a sickle hemoglobin variant together with a beta-thalassemia variant produces sickle beta-thalassemia, a form of sickle cell disease.

Inheritance and distribution

The common forms follow autosomal recessive inheritance, although rare dominantly inherited beta-thalassemia variants exist. If both parents carry a beta-thalassemia variant, each pregnancy has a 25% probability of a child inheriting two affected copies, a 50% probability of a carrier child, and a 25% probability of a child inheriting neither parental variant. The severity of an affected child’s disease depends on the variants and other modifying factors.

Alpha-thalassemia inheritance is more complex because four gene copies are usually involved. Two parents carrying two-gene deletions in the cis arrangement can have a child lacking all four alpha-globin genes.

Thalassemias are particularly frequent among populations with ancestry from the Mediterranean region, the Middle East, South Asia, Southeast Asia, and parts of Africa. Migration has made them relevant to health services worldwide. Their distribution partly reflects historical exposure to malaria, against which some carrier states confer partial protection. Ancestry alone neither establishes nor excludes the diagnosis.

Clinical features and complications

Carrier states often produce no symptoms and may be discovered through routine blood testing. More significant disease can cause pallor, tiredness, jaundice, reduced exercise tolerance, poor growth, and enlargement of the spleen.

Severe beta-thalassemia usually becomes apparent in infancy as fetal hemoglobin declines and beta-chain production becomes increasingly important. Untreated or inadequately controlled disease can cause marked marrow expansion, skeletal changes, and delayed growth and puberty.

Major complications include:

  • Iron overload. Repeated transfusions and increased intestinal absorption can deposit iron in the heart, liver, and endocrine organs. Consequences include heart failure, liver cirrhosis, diabetes mellitus, and impaired reproductive hormone function.
  • Bone disease. Marrow expansion, endocrine disturbances, and other factors can contribute to low bone density and osteoporosis.
  • Splenic enlargement and hypersplenism. An enlarged spleen can increase blood cell destruction and transfusion requirements.
  • Gallstones. Chronic hemolysis increases the risk of pigment stones.
  • Vascular complications. Some non-transfusion-dependent forms carry increased risks of thrombosis and pulmonary hypertension, particularly after splenectomy.

Complication patterns vary substantially with disease subtype, age, treatment history, and access to care.

Diagnosis

Evaluation combines blood counts, hemoglobin analysis, iron studies, and, when needed, molecular testing.

A complete blood count typically shows a low mean corpuscular volume, indicating small red blood cells. In thalassemia trait, the red blood cell count may be relatively high despite a low hemoglobin concentration. A blood smear can show small, pale cells and target cells, but these findings are not specific.

The principal differential diagnosis is iron-deficiency anemia. Ferritin and other iron measurements help distinguish the conditions, although inflammation can complicate ferritin interpretation. Red blood cell indices alone do not reliably establish the diagnosis.

Hemoglobin analysis by electrophoresis, high-performance liquid chromatography, or related methods measures the different hemoglobin fractions. Beta-thalassemia trait typically produces an elevated hemoglobin A₂ fraction, sometimes with increased fetal hemoglobin. Alpha-thalassemia trait often has normal adult hemoglobin fractions, so molecular analysis may be needed to confirm it.

Genetic testing can identify the causative variants and clarify reproductive risk. Recent transfusions and a person’s age can affect interpretation of hemoglobin testing.

Treatment

Treatment depends on clinical severity. Carrier states generally do not require thalassemia-specific therapy. Iron treatment addresses demonstrated coexisting iron deficiency, not the globin-production defect itself.

Transfusion and iron control

Regular blood transfusions are central to the care of transfusion-dependent disease. They improve oxygen delivery and suppress excessive marrow activity. Repeated transfusions can cause iron overload and the development of antibodies against donor red blood cell antigens.

Iron chelation therapy removes excess iron. Established drugs include deferoxamine, deferiprone, and deferasirox, which differ in administration, adverse effects, and monitoring requirements. Iron burden is assessed through serial laboratory measurements and organ-specific testing. Magnetic resonance imaging can quantify liver iron and assess cardiac iron accumulation; serum ferritin alone does not reliably characterize iron in every organ.

Disease-modifying and potentially curative treatment

Luspatercept, which promotes late-stage red blood cell maturation, can reduce transfusion burden in some adults with beta-thalassemia. Its approved indications vary by jurisdiction.

Hematopoietic stem cell transplantation from a donor can cure thalassemia by replacing the blood-forming system. Its risks include transplant-related illness, infertility, and graft-versus-host disease, and outcomes depend on factors including donor compatibility and pre-existing organ damage.

Gene therapy using a person’s own blood-forming stem cells offers another potentially curative approach for selected people with transfusion-dependent beta-thalassemia. Methods include adding a functional beta-globin gene and editing regulation of fetal hemoglobin production. These treatments require stem cell collection and conditioning chemotherapy. Eligibility, availability, and regulatory approval vary, and long-term follow-up remains important.

Splenectomy is used selectively because, although it may reduce transfusion needs in some circumstances, it increases the risks of serious infection and thrombosis.

Screening, counseling, and prognosis

Carrier screening can identify people whose children may be at risk of severe thalassemia. Genetic counseling explains inheritance, test limitations, and reproductive options. Prenatal diagnosis and preimplantation genetic testing can identify relevant variants when the familial genetic changes are known.

Prognosis differs greatly between carrier states and severe disease. Carrier states generally do not materially affect health or lifespan. For severe thalassemia, survival has improved substantially with reliable transfusion programs, iron chelation, organ monitoring, and transplantation. Access to these services remains uneven, and treatment burden, chronic complications, and the cost and availability of advanced therapies continue to shape outcomes.